Loading...

Loading...

NanoPass Brings Minimally Invasive MicronJet to Mexico
By Aura Moreno - Fri, 11/28/2025 - 17:47
NanoPass brings its MicronJet intradermal delivery to Mexico, strengthening access to precise and minimally invasive treatments.
https://mexicobusiness.news/tag/dermatology
More E-Commerce & Retail
L’Oréal Invests US$80M in Mexico to Grow Production Capacity
By MBN Staff - Thu, 08/14/2025 - 10:30
The country ranks among L’Oréal’s 10 most important markets worldwide, reaching more than 56 million households and serving as an export hub.
J&J Files for FDA Approval of Oral Psoriasis Drug Icotrokinra
By Sofía Garduño - Tue, 07/22/2025 - 08:17
J&J submits NDA for icotrokinra, an oral IL-23 blocker for plaque psoriasis, based on four Phase 3 trials showing strong efficacy and safety.
Addressing Dermatology Challenges in Mexico: LEO Pharma
By Sofía Garduño - Thu, 07/17/2025 - 09:23
Dermatology faces significant challenges in Mexico, highlighting the need to advance solutions for patients' needs, says LEO Pharma’s Ricardo Swain
Mexico's Virtual Consultation Evolution: Bridging Gaps
By Enrique Culebro - Fri, 06/13/2025 - 06:30
Virtual consultations face adoption hurdles due to financial expectations, preferences, and an evolving regulatory landscape, writes Enrique Culebro.
Mexican Health Expert Warns of Rising Melanoma Risks
By MBN Staff - Tue, 06/03/2025 - 17:11
Melanoma is deadly but treatable if caught early. Learn the signs, risks, and why no one is immune.
May Marks Push for Skin Cancer Awareness
By Sofía Garduño - Thu, 05/01/2025 - 10:00
Skin cancer rates are rising in Mexico and abroad, with experts urging prevention and early detection during Skin Cancer Awareness Month.
Dermatological Innovation, Biotech Evolve Natural Beauty
By Sofía Garduño - Wed, 11/20/2024 - 11:11
The dermatological market is expanding due to increased demand for natural looks and non-invasive treatments, explains Axios Pharma’s Angel Salgado.
FDA Approves Emrosi for Rosacea Lesions
By MBN Staff - Fri, 11/08/2024 - 09:20
The FDA approves Emrosi for rosacea lesions, set to launch in early 2025, expanding treatment options for this chronic condition.
EBGLYSS Effective in Treating Atopic Dermatitis After Dupilumab
By MBN Staff - Tue, 10/29/2024 - 16:18
Eli Lilly's Phase 3b ADapt study shows that EBGLYSS improves skin and reduces itch in atopic dermatitis patients not responding to dupilumab.